Effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction: A possible mechanism of prevention of cardiac events by angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk myocardial infarction

Internal Medicine

Volumn 48, Issue 11, 2009, Pages 877-882

  Tani, Shigemasa ^a,b   Nagao, Ken ^a,b   Anazawa, Takeo ^a,b   Kawamata, Hirofumi ^a,b   Furuya, Shingo ^a,b   Takahashi, Hiroshi ^a,b   Iida, Kiyoshi ^a,b   Matsumoto, Michiaki ^a,b   Kumabe, Narimichi ^a,b   Onikura, Motoyuki ^a,b   Hirayama, Atsushi ^b  

^a NIHON UNIVERSITY   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Left ventricular remodeling; Myocardial infarction

Indexed keywords

ENALAPRIL; LOSARTAN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REPERFUSION; HEART VENTRICLE REMODELING; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CARDIOTONIC AGENTS; ENALAPRIL; FEMALE; HUMANS; LOSARTAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECEPTORS, ANGIOTENSIN; RISK FACTORS; VENTRICULAR REMODELING;

EID: 67650086692     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.1948     Document Type: Article

References (13)

1. Dickstein K, Kjekshus J; The OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360: 752-760, 2002.
2. Pfeffer MA, McMurray JJ, Velazquez EJ; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893-1906, 2003.
3. Kim KS, Yoshiyama M, Izumi Y, et al. Effects of combination of ACE inhibitorand angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 103: 148-154, 2001.
4. Maia LN, Nicolau JC, Vítola JV, et al. Prospective evaluation comparing the effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction. Am Heart J 145: E 21, 2003.
5. Nagao K, Hayashi N, Kanmatsuse K, Kikuchi S, Ohuba T, Takahashi H; FAST Trial. An early and complete reperfusion strategy for acute myocardial infarction using fibrinolysis and subsequent transluminal therapy - The FAST trial. Circ J 66: 576-582, 2002.
6. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 369: 1208-1219, 2007.
7. Young JB, Dunlap ME, Pfeffer MA, et al; Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110: 2618-2626, 2004.
8. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators N Engl J Med 327: 669-677, 1992.
9. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345: 669-685, 1995.
10. GISSI-3 effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 343: 1115-1122, 1994.
11. Solomon SD, Skali H, Anavekar NS, et al. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation 111: 3411-3419, 2005.
12. Onodera H, Matsunaga T, Tamura Y, et al. Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction. Am Heart J 150: 689, 2005.
13. Ssraili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 14 Suppl 1: S 73-86, 2000.